<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00874653</url>
  </required_header>
  <id_info>
    <org_study_id>14175</org_study_id>
    <secondary_id>MA0711IT</secondary_id>
    <nct_id>NCT00874653</nct_id>
  </id_info>
  <brief_title>Survey on Patient Satisfaction Rate for Mirena Use in Heavy Menstrual Bleeding</brief_title>
  <official_title>Levonorgestrel Releasing Intrauterine System (MIRENA) in Idiopathic Menorrhagia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are:

        -  To evaluate patient satisfaction for efficacy and tolerability of heavy menstrual
           bleeding treatment by Mirena.

        -  To collect italian data for Mirena in clinical routine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The quality of life on the basis of the validated Health-Related Quality of Life questionnaire (HRQL SF-36)</measure>
    <time_frame>at 12 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">78</enrollment>
  <condition>Menorrhagia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel (Mirena, BAY86-5028)</intervention_name>
    <description>Women using Mirena for intrauterine treatment of menorrhagia</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with a diagnosis of idiopathic menorrhagia and Mirena inserted for a period no longer
        than three months according to the assessment of the investigator will be included in the
        study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women diagnosed with Idiopathic Menorrhagia and Mirena inserted for a period no longer
             than three months according to the assessment of the investigator and according to the
             international and national guidelines. These women should also accept to be on
             contraception during the time period that they have Mirena in situ

          -  Body Mass Index = 18-30

        Exclusion Criteria:

          -  One or more of the following disorders: Current or recurrent pelvic inflammatory
             disease; infection of the lower genital tract; postpartum endometritis; septic
             abortion during the past three months; cervicitis; cervical dysplasia; uterine or
             cervical malignancy; undiagnosed abnormal uterine bleeding; congenital or acquired
             abnormality of the uterus including fibroids if they distort the uterine cavity;
             conditions associated with increased susceptibility to infections; acute liver disease
             or liver tumor; known hypersensitivity to any of the constituents of the product

          -  Nulliparity

          -  Consumption of Iron, Antiprostaglandins, hormonal drugs and any medication that could
             effect bleeding should be stopped at least 3 months before the first visit and should
             not be used during the course of the study.

          -  History of diabetes mellitus, cardiovascular disease and thyroid abnormalities

          -  Anticoagulation therapy

          -  Cancer history including breast cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2009</study_first_submitted>
  <study_first_submitted_qc>April 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2009</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

